ArticlePostdoc journal : a journal of postdoctoral research and postdoctoral affairs2014
Many Roles of CCL20: Emphasis on Breast Cancer.
Article in Postdoc journal : a journal of postdoctoral research and postdoctoral affairs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.Breast cancer research : BCR · 2026Article
- Elevated CCL20 expression was associated with poor prognosis for breast cancer.Journal of the Chinese Medical Association : JCMA · 2025Article
- Thymoquinone Inhibition of Chemokines in TNF-α-Induced Inflammatory and Metastatic Effects in Triple-Negative Breast Cancer Cells.International journal of molecular sciences · 2023Article
- Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20-CCR6 axis.Cancer science · 2023Article
- EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.Science advances · 2022Article
- Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA.Nature methods · 2022Article
- Chemokine expression in patients with ovarian cancer or benign ovarian tumors.Archives of medical science : AMS · 2022Article
- Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression.Bioengineered · 2021Review
- EGR1 and RXRA transcription factors link TGF-β pathway and CCL2 expression in triple negative breast cancer cells.Scientific reports · 2021Article
- Probing Osteocyte Functions in Gelatin Hydrogels with Tunable Viscoelasticity.Biomacromolecules · 2021Article
- miR-19a mitigates hypoxia/reoxygenation-induced injury by depressing CCL20 and inactivating MAPK pathway in human embryonic cardiomyocytes.Biotechnology letters · 2021Article
- Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.American journal of cancer research · 2021Article
- Observational
- CC chemokines are differentially expressed in Breast Cancer and are associated with disparity in overall survival.Scientific reports · 2019Article
- Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer.Molecular oncology · 2019Article
- IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CCL20 or MIP3α is a small ~8 kDa protein primarily expressed in the liver, colon, prostate, cervix, and skin. The cellular receptor for CCL20 is CCR6. CCl20 unlike many other cytokines only binds CCR6, making the CCL20/CCR6 pathway an attractive drug target. Since the initial discovery of CCL20 in the early 1990's, there has been an increase in the evidence implicating the chemokine and its receptor in a number of diseases, including rheumatoid arthritis and human immunodeficiency virus infection. CCL20 has also been linked to malignancies such as ovarian, colorectal and pancreatic cancers. CCL20 can also attract tumor-promoting immune-suppressive cells to the tumor microenvironment, which may contribute to the immune evasive potential of the tumor and tumor progression.
Indexed as
Identifiers
27631019PMC5019369W2112925135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.